Misonix Primed For Stable Growth


Misonix, Inc’s (NASDAQ: MSON) CEO Stavros Vizirgianakis took time to update Wall Street Analyzer’s investment audience about the company’s recent developments. During the interview he discussed MSON’s Q3 results, which produced record revenues, and also outlined their partnership with Weigao in China. Mr. Vizirgianakis also provided an overview of Misonix Inc’s key products, SonicOne and BoneScalpel, and addressed how they position them in the wound care and spine surgery sectors. He also went over MSON’s goal of transitioning most of their business to the consumables space, and how that will make their revenues even more stable and predictable.




About Misonix:

Misonix, Inc. (NASDAQ: MSON) specializes in the development and commercialization of ultrasonic surgical devices for neurosurgical, spinal, advanced wound care, and general surgery procedures. Their portfolio of products are all based upon the unique properties of ultrasound and its ability to differentiate hard and soft tissue for different clinical requirements. Misonix, Inc. operates in over 45 countries and is a recognized leader in advanced surgical tools offering unprecedented safety, speed, and precision.


Company Contact:

Joe Dwyer Misonix, Inc.


Investor Contacts:

Robert Blum, Joe Dorame, Joe Diaz
Lytham Partners, LLC


About The Wall Street Analyzer 1500 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.